Please assess the completion status of the following clinical trial:

Trial Title: Phase III Study Investigating the Efficacy and Safety of Ruxolitinib in Early Myelofibrosis Patients With High Molecular Risk Mutations.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed diagnosis of MF with bone marrow fibrosis of at least Grade 1; irrespective of JAK2 mutational status~* Patients with at least one mutation in one of the five HMR genes (ASXL1, EZH2, SRSF2 and IDH1/2)~* Patients with non-palpable spleen or spleen palpable ≤ 5 cm from the left costal margin to the point of greatest splenic protrusion~* Patients with MF-7 score of ≤ 15, with each individual symptom score of ≤ 3~Exclusion Criteria:~* Patients with prior treatment with ruxolitinib or other JAK inhibitors.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ruxolitinib (Type: ACTIVE_COMPARATOR): Two tablets of ruxolitinib 5 mg were administered orally twice per day.
- Ruxolitinib Placebo (Type: PLACEBO_COMPARATOR): Two tablets of 5mg placebo were administered orally twice per day.

Based on this trial design, predict the completion outcome and termination type (if applicable).